Observational studyInternational urogynecology journal2017
Is mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder?
Observational study in International urogynecology journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Mirabegron versus vibegron in previously untreated female patients with overactive bladder: A randomized, single-clinic, open-label trial.Lower urinary tract symptoms · 2023Trial
- Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?International urogynecology journal · 2023Trial
- Benzodiazepines use and dependence in female patients with overactive bladder symptoms - prevalence and clinical correlations.Central European journal of urology · 2024Article
- Psychiatric History and Overactive Bladder Symptom Severity in Ambulatory Urogynecological Patients.Journal of clinical medicine · 2021Article
- Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?Current urology reports · 2020Review
- Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder.International urology and nephrology · 2020Article
- Real-World Effects of Mirabegron in Patients with Chronic Neurogenic Detrusor Overactivity - A Retrospective Cohort Study.Research and reports in urology · 2020Article
- The impact of Mirabegron on sexual function in women with idiopathic overactive bladder.BMC urology · 2019Observational
- Is it possible to cure the symptoms of the overactive bladder in women?International urology and nephrology · 2018Article
- Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder.International neurourology journal · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and hypothesisNo previous studies have investigated the efficacy of mirabegron 50 mg as the first-line therapy in OAB patients. Hence, the primary objective of this study was to evaluate the efficacy of mirabegron in treatment-naive patients in comparison with those who had discontinued antimuscarinic therapy because of insufficient efficacy.
methodsAll consecutive women who had pure OAB symptoms (including urgency with or without urgency incontinence and frequency) for at least 3 months were considered for this study. Women were divided into two groups: women without any previous pharmacological treatment for OAB (group 1) and women with a previous history of failed antimuscarinics therapy (group 2).
resultsAt 3-month follow-up, the objective results on the basis of the frequency-volume chart showed a significant improvement in both groups. Furthermore, a significant reduction in the Overactive Bladder Questionnaire Short Form (OABq-SF) score and in the Indevus Urgency Severity Scale (IUSS) questionnaire were reported in both groups. However, the improvement in objective and subjective outcomes was superior in group 1 to that in group 2.
conclusionsMirabegron is efficacious in improving OAB symptoms in both naïve patients and those who discontinued primary antimuscarinic therapy; however, its efficacy is superior when prescribed as first-line therapy.
Indexed as
Identifiers
27942790What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.